Department of Medicine

Imperial College Neuromodulation Group (ICNG)

logo

image

  • Drs. P Bain, Reader in Neurology and N Pavese & S Molloy Consultant Neurologists, Imperial College London
  • Mr. D Nandi, Consultant Neurosurgeon, Imperial College London
  • Dr. X Liu, Consultant Surgical Neurophysiologist, Imperial College London
  • Dr. D Murphy, Consultant Neuropsychologist, Imperial College Healthcare NHS Trust
  • Dr. N Yousif, Post-doctoral Scientist, Imperial College London
  • Mr. M J Naushahi, Clinical Research Fellow in Functional Neurosurgery, Imperial College London
  • J Watson, Administrator, Imperial College Healthcare NHS Trust (Tel: +44 (0) 20 3311 1182)

Research

  • The Group’s clinical and research interests lie in the classification, pathophysiology & management of patients with movement disorders, and in particular, the fascinating confluence of stereotactic functional neurosurgery (deep brain stimulation, DBS), the neurophysiology (local field potentials) of movement disorders (Parkinson's disease, essential tremor, MS tremor, dystonia), treatment resistant depression & chronic central pain (post-stroke pain, cluster headaches, other intractable neuropathic pain syndromes) and the electrical-brain interface generated by the DBS electrode in vivo.
  • Another area of clinical and research interest is the difficult field of primary malignant brain tumours. These tumours have resisted long years of extensive basic science and clinical studies aimed at improving the duration of survival and neurological functional outcome; the median survival after diagnosis of a primary high grade glial brain tumour today is about 12 - 15 months in spite of a combination of resective cranial surgery, radiotherapy and anti-neoplastic chemotherapy. The last three decades of scientific and technical sophistication have managed to enhance survival by barely 3-6 months. The Group is working on using the safer and highly accurate minimally-invasive deep intra-cerebral access provided by functional stereotactic neurosurgery, to target deep-seated brain tumours and deliver anti-neoplastic agents locally within the tumour at concentrations not possible to achieve by systemic means. The tools which are expected to come into play in the foreseeable future include individual tumour-tailored chemotherapy, multi-agent therapy, viral-vector delivery and sustained brachytherapy.

Awards & Prizes

Recent Publications

  1. Bain PG.  Parkinsonism & related disorders.  Tremor.  Parkinsonism Relat Disord.  13 Suppl 3: S369 – S374, 2007.  Publisher weblink DOI
  2. Nandi D; Jenkinson N; Stein J; Aziz T.  The pedunculopontine nucleus in Parkinson's disease: primate studies.  Br J Neurosurg22 Suppl 1: S4 – S8, 2008.  Publisher weblink DOI
  3. Liu X; Forster A.  Interventional neurophysiology: a new frontier in investigation, treatment and research.  Front Biosci13: 1691 – 1697, 2008.  Publisher weblink DOI
  4. Naushahi MJ, O’Riordan S, Bain PG, Aziz TZ, Nandi D.  Actual performance of the rechargeable Medtronic implantable pulse generator (Activa-RC) for deep brain stimulation (DBS) therapy in dystonia: a case report.  MDS Congress, Paris 2009.  [Mov Disord24 (1): S488 – S489, 2009]
  5. N Yousif, R Bayford & X Liu.  The influence of reactivity of the electrode-brain interface on the crossing electric current in therapeutic deep brain stimulation.  Neuroscience156: 597 – 606, 2008.  Publisher weblink DOI

Collaborations


Links


The UK’s first Academic Health Science Centre
incorporating St Mary’s and Hammersmith Hospitals in partnership with Imperial College London
Copyright © 2009, Imperial College Neuromodulation Group

Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook